Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment.
Temporary cART during primary HIV-infection (PHI) did not select for drug resistance mutations after treatment interruption and did not affect the subsequent virological response to long-term cART. Our data demonstrate that fear of drug resistance development is not a valid argument to refrain from...
Guardado en:
Autores principales: | Marlous L Grijsen, Ferdinand W N M Wit, Suzanne Jurriaans, Frank P Kroon, Emile F Schippers, Peter Koopmans, Luuk Gras, Joep M A Lange, Jan M Prins, Primo-SHM Study Group |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aa29d1b1c52a4b98a97ba1747b59e561 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.
por: Marlous L Grijsen, et al.
Publicado: (2012) -
Virology research and treatment.
Publicado: (2008) -
The immunological and virological consequences of planned treatment interruptions in children with HIV infection.
por: Nigel Klein, et al.
Publicado: (2013) -
ENVIRONMENTALLY FRIENDLY TEMPORARY ANTI-MOULD TREATMENT OF PACKAGING MATERIAL BEFORE DRYING
por: Welling,Johannes, et al.
Publicado: (2008) - Virology